16/09/2005
COLITE ULCEROSA: EFFICACE IL VSL#3!
15/09/2005
CANNABIS EFFICACE NELLE MALATTIE INFIAMMATORIE INTESTINALI
10/09/2005
Come usare gli immunosoppressori nella terapia delle IBD
Review article: practical management of inflammatory bowel disease patients taking immunomodulators.
Siegel CA, Sands BE.
Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16.
07/09/2005
Una nuova proposta per la terapia di pazienti con IBD steroidodipendenti
27/08/2005
5-ASA previene il cancro del colon: una metanalisi di studi osservazionali...
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Velayos FS, Terdiman JP, Walsh JM.
Am J Gastroenterol. 2005 Jun;100(6):1345-53.
19/08/2005
RCU: la terapia combinata è più efficace....
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M.
Gut. 2005 Jul;54(7):960-5.
15/08/2005
RCU: nuova terapia biologica.....
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK.
N Engl J Med. 2005 Jun 16;352(24):2499-507.
12/08/2005
Sorveglianza endoscopica nelle IBD-2
12/08/2005
Sorveglianza endoscopica nelle IBD-2
10/08/2005
Mycobacterium avium paratuberculosis causa la M.Crohn?
04/08/2005
Screening e trattamento della tubercolosi nei pazienti con malattia di Crohn
GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease.
Domenech E, Esteve M, Gomollon F, Hinojosa J, Panes J, Obrador A, Gassull MA; Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa.
Gastroenterol Hepatol. 2005 Mar;28(3):126-34.
03/08/2005
Infliximab terapia di salvataggio nelle coliti severe!!!!
21/07/2005
Sorveglianza endoscopica nelle IBD- 1
04/07/2005
la gestione dell’osteoporosi nei pazienti con IBD
American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.
Gastroenterology. 2003 Mar;124(3):791-4.
29/06/2005
I FATTORI DI STIMOLAZIONE MIDOLLARE RIDUCONO L'ATTIVITA'DEL CROHN!
26/06/2005
la vaccinazione dei pazienti con IBD
24/06/2005
Rischio di Leucemia e Linfoma nelle IBD
V.Annese Scrive"Risk of haematopoietic cancer in patients with inflammatory bowel diseaseAskling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A.CHAR(13) + CHAR(10)Gut 2005;54:617-622CHAR(13) + CHAR(10)
22/06/2005
AB nella prevenzione post-chirurgica del Crohn. Meno recidive ma molti drop-out
V.Annese Scrive"Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trialCHAR(13) + CHAR(10)Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F.CHAR(13) + CHAR(10)Gastroenterology 2005;128:856
20/06/2005
Crohn fistolizzante: infliximab terapia di mantenimento ideale!!!
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE.
Gastroenterology. 2005 Apr;128(4):862-9.
27/05/2005
CENSIMENTO ITALIANO DEGLI AMBULATORI PER LE M.I.C.I.
27/05/2005
CENSIMENTO ITALIANO DEGLI AMBULATORI PER LE M.I.C.I.
15/05/2005
MORBO DI CROHN, MESSE A PUNTO NUOVE MOLECOLE
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma}.
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P.
J Exp Med. 2005 Apr 18;201(8):1205-15.
27/04/2005
Smettere di fumare modifica il decorso della malattia di Crohn
09/04/2005
NUOVA PROMETTENTE TERAPIA NELLA MALATTIA DI CROHN REFRATTARIA
Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease.
Yu Oyama, Robert M. Craig, Ann E. Traynor, Kathleen Quigley, Laisvyde Statkute, Amy Halverson, Mary Brush, Larissa Verda, Barbara Kowalska, Nela Krosnjar, Morris Kletzel, Peter F. Whitington, Richard K. Burt.
Gastroenterology 2005 Mar;128(3):552-63.
Background & Aims: Crohn’s disease (CD) is an immunologically mediated inflammatory disease of the gastrointestinal tract. Due to a high morbidity and/or an increase in mortality in refractory cases, a new treatment approach is needed. In theory, maximum immune ablation by autologous hematopoietic stem cell transplantation (HSCT) can induce a remission. Methods: We conducted a phase 1 HSCT study in 12 patients with refractory CD. Candidates were younger than 60 years of age with a Crohn’s Disease Activity Index (CDAI) of 250–400 despite conventional therapies including infliximab. Peripheral blood stem cells were mobilized with cyclophosphamide and granulocyte colony-stimulating factor and CD34+ enriched. The immune ablative (conditioning) regimen consisted of 200 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin. Results: The procedure was well tolerated with anticipated cytopenias, neutropenic fever, and disease-related fever, diarrhea, anorexia, nausea, and vomiting. The median days for neutrophil and platelet engraftment were 9.5 (range, 8–11) and 9 (range, 9–18), respectively. The initial median CDAI was 291 (range, 250–358). Symptoms and CDAI improved before hospital discharge, whereas radiographic and colonoscopy findings improved gradually over months to years following HSCT. Eleven of 12 patients entered a sustained remission defined by a CDAI ≤150. After a median follow-up of 18.5 months (range, 7–37 months), only one patient has developed a recurrence of active CD, which occurred 15 months after HSCT. Conclusions: Autologous HSCT may be performed safely and has a marked salutary effect on CD activity. A randomized study will be needed to confirm the efficacy of this therapy.
02/04/2005
TERAPIA MEDICA E CHIRURGICA PER LA COLITE ULCEROSA. una buona review!
20/03/2005
Anti-transglutaminasi: Un nuovo marker molecolare nella colite ulcerosa
06/03/2005
M.di Crohn: è utile l'etidronato nel trattamento dell'osteopenia???
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G.
Clin Gastroenterol Hepatol. 2005 Feb;3(2):122-32.
Background & Aims: Crohn's disease causes an increase in osteopenia and osteoporosis. This study assessed the efficacy of adding etidronate to calcium and vitamin D supplementation for treatment of low bone mineral density in Crohn's disease. Methods: One hundred fifty-four patients with Crohn's disease with decreased bone mineral density, determined by using dual-energy x-ray absorptiometry, were randomly assigned to receive etidronate (400 mg orally) or not for 14 days; both groups were then given daily calcium (500 mg) and vitamin D (400 IU) supplementation for 76 days. This cycle was repeated 8 times during a period of 24 months. Biochemical characteristics and bone mineral densities were assessed at 6, 12, and 24 months. Results: After 24 months bone mineral density significantly increased from baseline in both the etidronate- and the non-etidronate-treated groups (both groups receiving calcium and vitamin D supplementation) at the lumbar spine ( P
05/03/2005
L'endoscopia non è necessaria per monitorare la rettocolite ulcerosa
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
Higgins PD, Schwartz M, Mapili J, Zimmermann EM.
Am J Gastroenterol 2005;100:1-7.
OBJECTIVES: Many disease activity indices are used to measure ulcerative colitis. Invasive indices incorporate an endoscopic score, while noninvasive indices do not require endoscopy. In clinical practice, many patients are treated based on their symptoms without endoscopic evaluation. However, invasive indices are commonly used in clinical research. Our objective was to determine whether endoscopy is necessary for the assessment of disease activity in patients with ulcerative colitis. METHODS: Sixty-six consecutive ulcerative colitis patients were evaluated with invasive indices: the St. Mark's index and the Ulcerative Colitis Disease Activity Index (UCDAI); and noninvasive indices: the Simple Clinical Colitis Activity Index (SCCAI) and the Seo index. The correlations between the indices were measured. The contribution of the endoscopic items was measured with linear regression modeling. The overlap of endoscopy with other items in the standard indices was determined through factor analysis. RESULTS: The two noninvasive indices correlated well with the invasive St. Mark's Index (SCCAI 0.86, Seo 0.70). After adjusting for the three noninvasive UCDAI items, the UCDAI endoscopy item predicted only 0.04% of the variance in the St. Mark's index. Factor analysis demonstrated that this is because the endoscopy items in the invasive indices correlate with stool frequency and stool blood items. CONCLUSIONS: Endoscopy items contribute little additional information to indices of disease activity in ulcerative colitis. The clinical practice of treating patients based on reported symptoms is appropriate. The use of noninvasive indices in clinical trials could lower study costs and may increase subjects' willingness to participate.
20/02/2005
FANS e riacutizzazioni delle IBD; nessuna prova certa di una associazione
gimmy Scrive"Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?CHAR(13) + CHAR(10)Forrest K, Symmons D, Foster P.CHAR(13) + CHAR(10)Aliment Pharmacol Ther. 2004 Nov 15;20(10):1035-43.CHAR(13) + CHAR(10)
08/02/2005
DURANTE LA GRAVIDANZA L’USO DELL’ INFLIXIMAB È SICURO
05/02/2005
LA SUPPLEMENTAZIONE CON ACIDO FOLICO RIDUCE LA TOSSICITÀ DA METOTREXATE
Folate, Homocysteine, and Cobalamin Status in Patients with Rheumatoid Arthritis Treated with Methotrexate, and the Effect of Low Dose Folic Acid Supplement .
NETE HORNUNG, TORKELL ELLINGSEN, KRISTIAN STENGAARD-PEDERSEN, and JØRGEN H. POULSEN.
J Rheumatol 2004;31:2374-81.
04/02/2005
Colonscopia virtuale in RMN un nuovo strumento diagnostico nelle IBD
01/02/2005
Uova di elminti: una nuova terapia nella malattia di Crohn
01/02/2005
L'uso di narcotici peggiora la malattia di Crohn
Narcotic use in patients with Crohn's disease.
Cross RK, Wilson KT, Binion DG.
Am J Gastroenterol. 2005 Oct;100(10):2225-9.
21/01/2005
M. di Crohn: l'uso di immunosoppressori riduce il rischio di complicanze
15/01/2005
Un nuovo anti-TNF è efficace nel trattamento del M.di Crohn
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A; CDP870 Crohn's Disease Study Group.
Gastroenterology. 2005 Sep;129(3):807-18.
14/01/2005
L'infliximab migliora la densità ossea nel m.di Crohn
Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
Bernstein M, Irwin S, Greenberg GR.
Am J Gastroenterol. 2005 Sep;100(9):2031-5.